Interleukin Related Inhibitor

Neuroprotective agent 18 is a potent neuroprotective agent. Neuroprotective agent 18 inhibits the activity of NF-κB thereby significantly downregulating the expression of downstream pro-inflammatory mediators (TNF-α, IL-6) and inflammatory enzymes (COX-2) in the hippocampus. Neuroprotective agent 18 binds to AChE thereby partially inhibiting it and modulating cholinergic neurotransmission. Neuroprotective agent 18 can be used in research on Alzheimer's disease.

IL4 Human Pre-designed siRNA Set A contains three designed siRNAs for IL4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TQC2938 is a humanized IgG2 monoclonal antibody inhibitor targeting Stimulation-2 (ST2). TQC2938 inhibits the ST2/IL-33 signaling pathway, reduces the level of downstream Th2 cytokines (such as IL-4, IL-5, and IL-13) and eosinophils as well as other inflammatory cells. TQC2938 can be used for inflammatory diseases like asthma research.

NEK7-IN-2 is a NEK7 inhibitor. NEK7-IN-2 increases the thermal stability of NEK7, disrupts the NEK7-NLRP3 interaction, inhibits NLRP3 inflammasome assembly, and suppresses the release of IL-1β (with an IC₅₀ of 0.048 μM against IL-1β). NEK7-IN-2 can be used for the research of inflammatory diseases.

PROTAC PDE4 degrader-1 is an orally active CRBN-recruiting PDE4B PROTAC degrader. PROTAC PDE4 degrader-1 shows an IC₅₀ of 1.9 μM against PDE4B, degrades PDE4B via the ubiquitin-proteasome pathway, and shows weak activity against PDE4C. PROTAC PDE4 degrader-1 inhibits the secretion of pro-inflammatory cytokines TNF-α and IL-6, reduces the infiltration of inflammatory cells into lung tissues, protects lung tissues and alleviates acute lung injury. PROTAC PDE4 degrader-1 can be used for the research of acute lung injury.

Anti-inflammatory agent 59 is an anti-inflammatory agent. Anti-inflammatory agent 58 inhibits IL-1β with an IC₅₀ of 2.28 μM. Anti-inflammatory agent 58 decreases pro-inflammatory gene expression, protein secretion, and NF-κB phosphorylation.

Acutissimalignan B is a natural product. Acutissimalignan B can be isolated from Daphne kiusiana var. atrocaulis (Rehd.) F. Maekawa. Acutissimalignan B can reduce the mRNA expression of inflammatory cytokines (iNOS, TNF-α, IL-1β, and IL-6), inhibit the phosphorylation of IκBα, and inhibit the nuclear translocation of NK-κB p65. Acutissimalignan B shows anti-neuroinflammatory effects.

PMX464 (AW 464) is a thiol-reactive quinol compound and an inhibitor of the thioredoxin-thioredoxin reductase (Trx/TrxR) system, with an IC₅₀ value of 6.5 μM against TrxR. PMX464 acts by irreversibly inhibiting the thioredoxin (Trx-1) system, blocking HIF-1α transcriptional activation and the NF-κB inflammatory pathway, inducing apoptosis, attenuating platelet function and inhibiting thrombosis, and specifically disrupting the trypanothione antioxidant metabolic network in parasites. PMX464 is used in research concerning malignant tumors (colorectal cancer, breast cancer, renal cancer, and leukemia), pulmonary inflammation, African sleeping sickness, and antithrombotic applications.

SHP2-IN-45 (Compound 6) is a potent, highly selective, and orally active SHP2 allosteric inhibitor. SHP2-IN-45 significantly reduces the expressions of IL-6, TNF-α, IL-1β, and iNOS. SHP2-IN-45 inhibits the polarization of M1-type macrophages. SHP2-IN-45 can inhibit the NF-κB pathway. SHP2-IN-45 can be used in the research of sepsis and acute lung injury.

VDJ001 is a high-affinity humanized anti-IL-6R monoclonal antibody. VDJ001 can be used for the study of rheumatoid arthritis.

Il10 Rat Pre-designed siRNA Set A contains three designed siRNAs for Il10 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Anti-Human/Mouse GRP78 Antibody (N88) is an anti-human/mouse GRP78 IgG1 monoclonal antibody. Anti-Human/Mouse GRP78 Antibody (N88) can activate the Akt signaling pathway. Anti-Human/Mouse GRP78 Antibody (N88) can inhibit the expression of inflammatory factors and plasminogen activator inhibitors induced by TLR agonists. Anti-Human/Mouse GRP78 Antibody (N88) can be used for research on inflammation conditions. Anti-Human/Mouse GRP78 Antibody (N88) can be used for immunoprecipitation.

IL23A Human Pre-designed siRNA Set A contains three designed siRNAs for IL23A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

COX-2-IN-63 (Compound 6k) is an orally active COX-2 inhibitor with an IC₅₀ of 0.89 μM. COX-2-IN-63 reduces the levels of inflammatory mediators PGE2, TNF-α, and IL-6. COX-2-IN-63 can effectively alleviate acute inflammation in a rat paw edema model and has a lower risk of gastrointestinal side effects. COX-2-IN-63 can be used in anti-inflammatory research.

BuChE-IN-23 is an orally active, blood-brain barrier permeable butyrylcholinesterase (eqBuChE) inhibitor with an IC₅₀ of 15.59 μM and a K_i of 29.33 μM. BuChE-IN-23 exhibits an IC₅₀ of 38.65 μM against hBuChE and shows selectivity for butyrylcholinesterase over acetylcholinesterase. BuChE-IN-23 inhibits LPS (HY-D1056)-induced nitric oxide production, attenuates hippocampal glial cell activation and neuroinflammation, suppresses the TLR4/p38 MAPK signaling pathway, and regulates the IL-1β/C3-mediated microglia-astrocyte inflammatory axis. BuChE-IN-23 can be used for the research of Alzheimer's disease.

MT204 is a humanized IgG1 antibody inhibitor targeting IL-2 of human and rhesus monkey origin. MT204 prevents soluble IL-2 from binding to intermediate-affinity IL-2 receptors and blocks CD25-bound IL-2 on high-affinity IL-2 receptors. MT204 has potently anti-proliferative activity with NKL cells and primary NK cells. MT204 has good tolerability and potent immunosuppressive activity in allogeneic skin graft model of rhesus monkey, promising for immunosuppressive and anti-proliferative therapy.

Isopongaflavone is an isoflavone that can be isolated from the seedpods of Tephrosia vogelii with anti-inflammatory effects. Isopongaflavone suppresses the secretion of IL-1β, IFN-γ, granulocyte macrophage-colony stimulating factor (GM-CSF) and TNF-α in LPS (HY-D1056)-stimulated peripheral blood mononuclear cells (PBMCs).

PARP14 inhibitor 1 is an orally active, selective PARP14 inhibitor with an IC₅₀ of 5.52 nM. PARP14 inhibitor 1 exhibits favorable pharmacokinetic properties and in vivo safety. PARP14 inhibitor 1 enhances and stabilizes intracellular endogenous PARP14 protein levels, while effectively reducing the expression levels of IL-4, IL-13 and IL-17A. PARP14 inhibitor 1 can be used in research related to atopic dermatitis.

Ppc-1 is a mitochondrial uncoupler. Ppc-1 enhances mitochondrial oxygen consumption without adverse effects on ATP production. Ppc-1 is a cell-permeate interleukin-2 (IL-2) inhibitor. Ppc-1 inhibits the Gram-negative periodontopathogen Porphyromonas gingivalis. Ppc-1 has anti-obesity, antibacterial and anti-inflammatory activities.

LT-1339-553 is a selective, orally active RIPK1 inhibitor with IC₅₀ values of 4.32, 95.74 and 84.33 nM against RIPK1, RIPK2 and RIPK3, respectively. LT-1339-553 exerts anti-necroptotic activity by inhibiting the AKT/PI3K/NF-κB pathway and the IL-17 pathway. LT-1339-553 reduces liver injury, inflammatory responses and collagen deposition. LT-1339-553 can be used in studies related to schistosomiasis-induced liver fibrosis.